FDA 'spec-in' creates durable regulatory moat
The guest explained that Stevanato's business model benefits from a powerful regulatory lock-in, where drug developers must specify a containment/delivery system early in the R&D process and cannot easily switch suppliers.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.